Bone turnover markers and bone scintigraphy in the evaluation of skeletal metastases

Nuclear Medicine Review

Volumn 8, Issue 2, 2005, Pages 100-104

  Chrapko, Beata E ^a   Nocuń, Anna ^a   Gołebiewska, Renata ^a   Jankowska, Helena ^a   Zaorska Rajca, Janina ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Bone scintigraphy; Bone turnover markers; Skeletal metastases

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; MEDRONATE TECHNETIUM TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE DEFECT; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DISSEMINATED CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OSSIFICATION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TECHNETIUM TC 99M MEDRONATE; TUMOR MARKERS, BIOLOGICAL;

EID: 30944446475     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Stajszczyk M, Mykała-Cieśla J. Bisphosphonates in the treatment of breast carcinoma. Pol Arch Int Med 2001; 2: 729-738.
2. Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone: review. Ann Nucl Med 2002; 16: 161-168.
3. Tahtela R, Tholix E. Serum concentration of type I collagen carboxy-terminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996; 16: 2289-2293.
4. Noguchi M, Noda S. Piridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001; 166: 1106-1111.
5. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of amino-terminal propeptide of type I procollagen am a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001; 87: 348-351.
6. Buscombe JR, Holloway B, Roche N, Bombardieri E. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging 2004; 48: 109-118.
7. Bombardieri E, Aktolun C, Baum RP et al. Bone scintigraphy: procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imag 2003; 30: BP99-BP106.
8. Einthorn TA, Vigorita VJ, Aaron A. Localization of technetium-99m methylene diphosphonate in bone using microradiography. J Orthop Res 1986; 4: 180-187.
9. Van der Wall H. The evaluation of malignancy: metastatic bone disease. Murray ]PC, Ell PJ (eds). Nuclear Medicine in clinical diagnosis and treatment. Churchill Livingstone, Edinburgh 1994: 949-962.
10. Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imag 2004; 31 (Suppl 1): 143-148.
11. Crippa F, Seregni E, Agresti R, Bombardieri E, Buraggi GL. Bone scintigraphy in breast cancer: ten years follow up study. J Nucl Biol Med 1993; 37: 57-61.
12. Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer 2003; 2: 34-40.
13. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extend of disease on initial bone scan. Cancer 1988; 61: 195-202.
14. Konieczna M, Pietrzykowski J, Chmielowski K, Dziuk E. The possibility of qualification patients suspected of bone metastases for skeletal scintigraphy according to concentration of collagen turnover markers. Nucl Med Rev Cent East Eur 2002; 1: 73.
15. Berruti A, Dogliotti L, Gorzegno G et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45: 1240-1247.
16. Luftner D, Richter A, Geppert R, Wernecke KD, Possinger K. Normalization of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 2003; 23: 1017-1026.
17. Schoenberger J, Rozeboom S, Wirthgen-Bever E, Eilles C. Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy. BMC Nucl Med 2004; 4: 3.
18. Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004; 24: 3193-3201.
19. Noguchi M, Yahara J, Noda S. Serum level of bone turnover marker parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003; 61: 993-998.
20. Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003; 23: 4095-4099.
21. Jukkola A, Bloigu R, Holli K and al. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 2001; 21: 2873-2876.
22. Ylisirnio S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 1999; 19: 5577-5581.
23. Simojoki M, Santala M, Risteli J, Kauppila A. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. Gynecol Oncol 2003; 88: 358-362.
24. Kobayashi T, Gabazza EC, Taguchi O et al. Type I collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 1999; 85: 1951-1957.